collaboration-proxygen-molecular-glue-degraders collaboration-proxygen-molecular-glue-degraders Boehringer Ingelheim collaborates with Proxygen to explore molecular glue degraders – a novel approach to fight cancer.
Two new claims for Nexgard range in EU and Australia Two new claims for Nexgard range in EU and Australia Boehringer Ingelheim expands the label claims of its NexGard® brands for the treatment of two severe skin diseases in dogs in the EU and in Australia.
Fight against COVID-19 pandemic Fight against COVID-19 pandemic Press release on Boehringer Ingelheim's half-year figures 2020. Business development from January to June 2020.
AI&Data Science Fellowship Tuebingen AI&Data Science Fellowship Tuebingen AI&Data Science Fellowship Tuebingen
Rethinking mental health care Rethinking mental health care Outdated perceptions and practices fuelling mental health crisis, new Economist Impact study reveals
World Veterinary Day aspects veterinary profession World Veterinary Day aspects veterinary profession • World Veterinary Day 2024 celebrates the essential work of veterinarians, yet new data show only 49% of veterinary professionals believe their profession is appreciated.
InSensitive Content: the impact on dermatologists InSensitive Content: the impact on dermatologists Learn about the importance of the dermatology community sharing content related to generalized pustular psoriasis on social media.
New indications NexGard, NexGard SPECTRA and Broadline New indications NexGard, NexGard SPECTRA and Broadline New therapeutic indications for NexGard®, NexGard SPECTRA® and Broadline® approved by EMA